370 related articles for article (PubMed ID: 10700588)
1. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
2. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
Pugh G; Mason DJ; Combs V; Welch SP
J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
[TBL] [Abstract][Full Text] [Related]
3. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
[TBL] [Abstract][Full Text] [Related]
5. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.
Welch SP
Drug Alcohol Depend; 1997 Apr; 45(1-2):39-45. PubMed ID: 9179505
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions of endogenous opioids and cannabinoid systems.
Welch SP; Eads M
Brain Res; 1999 Nov; 848(1-2):183-90. PubMed ID: 10612710
[TBL] [Abstract][Full Text] [Related]
7. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
8. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
Smith FL; Fujimori K; Lowe J; Welch SP
Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
[TBL] [Abstract][Full Text] [Related]
9. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
10. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
11. Dynorphin-independent spinal cannabinoid antinociception.
Gardell LR; Ossipov MH; Vanderah TW; Lai J; Porreca F
Pain; 2002 Dec; 100(3):243-248. PubMed ID: 12467995
[TBL] [Abstract][Full Text] [Related]
12. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta.
O'Sullivan SE; Kendall DA; Randall MD
Eur J Pharmacol; 2005 Jan; 507(1-3):211-21. PubMed ID: 15659311
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
14. Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (Δ
Henderson-Redmond AN; Sepulveda DE; Ferguson EL; Kline AM; Piscura MK; Morgan DJ
Psychopharmacology (Berl); 2022 May; 239(5):1289-1309. PubMed ID: 34165606
[TBL] [Abstract][Full Text] [Related]
15. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.
Pugh G; Smith PB; Dombrowski DS; Welch SP
J Pharmacol Exp Ther; 1996 Nov; 279(2):608-16. PubMed ID: 8930163
[TBL] [Abstract][Full Text] [Related]
16. (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure.
Burkey RT; Nation JR
Exp Clin Psychopharmacol; 1997 Aug; 5(3):195-202. PubMed ID: 9260067
[TBL] [Abstract][Full Text] [Related]
17. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
Smith PB; Compton DR; Welch SP; Razdan RK; Mechoulam R; Martin BR
J Pharmacol Exp Ther; 1994 Jul; 270(1):219-27. PubMed ID: 8035318
[TBL] [Abstract][Full Text] [Related]
18. A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors.
Xiong W; Wu X; Li F; Cheng K; Rice KC; Lovinger DM; Zhang L
J Neurosci; 2012 Apr; 32(15):5200-8. PubMed ID: 22496565
[TBL] [Abstract][Full Text] [Related]
19. Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice.
Fride E; Mechoulam R
Brain Res Dev Brain Res; 1996 Aug; 95(1):131-4. PubMed ID: 8873985
[TBL] [Abstract][Full Text] [Related]
20. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
